Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Roy, Pollock"'
Autor:
Tim Clackson, Frank Wang, John D. Iuliucci, Narayana I. Narasimhan, Roy Pollock, Yaoyu Ning, Scott D. Wardwell, Lori Berk, David Miller, Rachel M. Squillace, Victor M. Rivera
Supplementary Figure 3 from Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a55a658107edbacb04f85646bc213606
https://doi.org/10.1158/1535-7163.22496250.v1
https://doi.org/10.1158/1535-7163.22496250.v1
Autor:
Tim Clackson, Frank Wang, John D. Iuliucci, Narayana I. Narasimhan, Roy Pollock, Yaoyu Ning, Scott D. Wardwell, Lori Berk, David Miller, Rachel M. Squillace, Victor M. Rivera
The mTOR pathway is hyperactivated through oncogenic transformation in many human malignancies. Ridaforolimus (AP23573; MK-8669) is a novel rapamycin analogue that selectively targets mTOR and is currently under clinical evaluation. In this study, we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1569b6d231c9801039f6c0365f86e4e7
https://doi.org/10.1158/1535-7163.c.6535203
https://doi.org/10.1158/1535-7163.c.6535203
Autor:
Tim Clackson, Frank Wang, John D. Iuliucci, Narayana I. Narasimhan, Roy Pollock, Yaoyu Ning, Scott D. Wardwell, Lori Berk, David Miller, Rachel M. Squillace, Victor M. Rivera
Supplementary Figure 1 from Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31157ac1340d347481ad2e92f31f6667
https://doi.org/10.1158/1535-7163.22496256
https://doi.org/10.1158/1535-7163.22496256
Autor:
Tim Clackson, Frank Wang, John D. Iuliucci, Narayana I. Narasimhan, Roy Pollock, Yaoyu Ning, Scott D. Wardwell, Lori Berk, David Miller, Rachel M. Squillace, Victor M. Rivera
Supplementary Figure Legends from Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::439392f02e858cecdc3c943bce799317
https://doi.org/10.1158/1535-7163.22496247
https://doi.org/10.1158/1535-7163.22496247
Autor:
Tim Clackson, Frank Wang, John D. Iuliucci, Narayana I. Narasimhan, Roy Pollock, Yaoyu Ning, Scott D. Wardwell, Lori Berk, David Miller, Rachel M. Squillace, Victor M. Rivera
Supplementary Table 1 from Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29bf4f4d96fd3dfbf968b8c8066295f5
https://doi.org/10.1158/1535-7163.22496244.v1
https://doi.org/10.1158/1535-7163.22496244.v1
Autor:
Tim Clackson, Frank Wang, John D. Iuliucci, Narayana I. Narasimhan, Roy Pollock, Yaoyu Ning, Scott D. Wardwell, Lori Berk, David Miller, Rachel M. Squillace, Victor M. Rivera
Supplementary Figure 2 from Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4eeceb9b398b313ae4df947905f9c06b
https://doi.org/10.1158/1535-7163.22496253
https://doi.org/10.1158/1535-7163.22496253
Autor:
Cloud P Paweletz, Jannik N Andersen, Roy Pollock, Kumiko Nagashima, Mansuo L Hayashi, Shangshuan U Yu, Hongbo Guo, Ekaterina V Bobkova, Zangwei Xu, Alan Northrup, Peter Blume-Jensen, Ronald C Hendrickson, An Chi
Publikováno v:
PLoS ONE, Vol 6, Iss 10, p e26459 (2011)
Pharmacodynamic (PD) biomarkers are an increasingly valuable tool for decision-making and prioritization of lead compounds during preclinical and clinical studies as they link drug-target inhibition in cells with biological activity. They are of part
Externí odkaz:
https://doaj.org/article/ecc88f9d2bf143f09228d27bcd3a4329
Autor:
Kumiko, Nagashima, Stuart D, Shumway, Sriram, Sathyanarayanan, Albert H, Chen, Brian, Dolinski, Youyuan, Xu, Heike, Keilhack, Thi, Nguyen, Maciej, Wiznerowicz, Lixia, Li, Bart A, Lutterbach, An, Chi, Cloud, Paweletz, Timothy, Allison, Youwei, Yan, Sanjeev K, Munshi, Anke, Klippel, Manfred, Kraus, Ekaterina V, Bobkova, Sujal, Deshmukh, Zangwei, Xu, Uwe, Mueller, Alexander A, Szewczak, Bo-Sheng, Pan, Victoria, Richon, Roy, Pollock, Peter, Blume-Jensen, Alan, Northrup, Jannik N, Andersen
Phosphoinositide-dependent kinase 1 (PDK1) is a critical activator of multiple prosurvival and oncogenic protein kinases and has garnered considerable interest as an oncology drug target. Despite progress characterizing PDK1 as a therapeutic target,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::ffa77558274950b04bf7d0ff36cc73f0
http://hdl.handle.net/10722/156005
http://hdl.handle.net/10722/156005
Autor:
Roy Pollock
Publikováno v:
Current Protocols in Molecular Biology
Binding-site selection is used to determine the target specificity of a sequence-specific DNA-binding protein. In this unit, a pool of random-sequence oligonucleotides is used as the source of potential binding sites. This pool is incubated with extr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da687defc4f8e14674ad0544031f0e9e
https://pubmed.ncbi.nlm.nih.gov/18265083
https://pubmed.ncbi.nlm.nih.gov/18265083
Autor:
Roy Pollock, Richard Treisman
Publikováno v:
Nucleic Acids Research. 18:6197-6204
We describe a sensitive and rapid method for determination of the sequence specificity of DNA binding proteins. The method allows recovery of specific sites using the small amounts of protein present in crude cell extracts or produced by cell-free tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d79cdc153a0e1e9eaabc395dd98b1e2
https://doi.org/10.1093/nar/18.21.6197
https://doi.org/10.1093/nar/18.21.6197